Brief: Shinpoong Pharmaceutical Applies For 3Rd Phase Clinical Trial Approval For Osteoarthritis Injection Treatment From S.Korea Ministry Of Food And Drug Safety
15/11/2022 07:22
Shinpoong Pharmaceutical Co Ltd 019170.KS :
* SHINPOONG PHARMACEUTICAL: APPLIES FOR 3RD PHASE CLINICAL
TRIAL
APPROVAL FOR OSTEOARTHRITIS INJECTION TREATMENT FROM S.KOREA
MINISTRY OF FOOD AND DRUG SAFETY
Source text for Eikon: ID:
Further company coverage: 019170.KS
Recent news on SHINPOONG PHARMACEUTICAL
See all newsBrief: Shinpoong Pharmaceutical To Divest 11.5 Billion Won Worth Of Own Shares
Brief: Shinpoong Pharmaceutical To Invest 62.4 Billion Won In Facilities
Brief: Shinpoong Pharmaceutical Co Wins 10 Billion Won Order
Brief: Shinpoong Pharmaceutical Wins 13 Billion Won Order
Brief: Shinpoong Pharmaceutical Applies For 3Rd Phase Clinical Trial Approval For Osteoarthritis Injection Treatment From S.Korea Ministry Of Food And Drug Safety